Clinical study on deanxit in the treatment of post-stroke depression
10.3760/cma.j.issn.1008-6706.2011.17.002
- VernacularTitle:氟哌噻吨/美利曲辛治疗脑卒中后抑郁60例疗效分析
- Author:
Aiguo SUN
;
Ruihong SUN
- Publication Type:Journal Article
- Keywords:
Flupentixol/melitracen;
Depression;
Cerebrovascular accident
- From:
Chinese Journal of Primary Medicine and Pharmacy
2011;18(17):2307-2308
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy of deanxit in treatment of post-stroke depression (PSD).Methods60 patients with PSD were randomly divided into treatment group ( plus with deanxit) and control group (plus with estazolam necessarily). At the baseline and at 2 weeks,4 weeks, 8 weeks after the treatment, the efficacy was assessed with HAMD, SSS, and ADL rating scale respectively. Results After 2,4,8 weeks treatment, HAMD and SSS scores of the treatment group significantly decreased compared with the control group ( all P ＜ 0. 01 ), and ADL scores of the treatment group increased significantly compared with the control group ( P ＜ 0. 01 ). Conclusion Deanxit could effectively relieve depressing symptoms and neurological impairment of PSD, and clinical side effects of deanxit were less. Deanxit was suitable for acute phase and long-term maintenance therapy in PSD.
